

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-58 (canceled).

59 (currently amended). A CD23-binding peptide, wherein said peptide consists of:

Phe-His-Glu-Phe-Trp-Pro-Thr	(SEQ ID NO:2);
Phe-His-Ser-Gln-Trp-Pro-Asn	(SEQ ID NO:3);
Phe-His-Glu-Asn-Trp-Pro	(SEQ ID NO:4);
Phe-His-Glu-Asn-Trp-Pro-Thr	(SEQ ID NO:5);
Phe-His-Glu-Gln-Trp-Pro-Ser	(SEQ ID NO:6);
His-Glu-Asn-Trp-Pro-Ser	(SEQ ID NO:7);
His-Lvs-Asn-Trp-Pro-Ser	(SEQ ID NO:8);
His-Glu-Asn-Trp-Pro-Ser-Phe	(SEQ ID NO:9);
Phe-His-Lys-Pro-Trp-Arg-Ala	(SEQ ID NO:10);
His-Glu-Asn-Trp-Lys-Ser	(SEQ ID NO:31);
His-Glu-Asn-Trp-Xaa-Ser	(SEQ ID NO:32);
His-Glu-Asn-Trp-Gly-Ser	(SEQ ID NO:34);
His-Glu-Asn-Trp-Glu-Ser	(SEQ ID NO:35);
Phe-His-Glu-Ala-Trp-Pro-Ser	(SEQ ID NO:40);
Phe-His-Glu-Asn-Trp-Xaa-Ser	(SEQ ID NO:43);

His-Glu-Asn-Ala-Pro-Ser	(SEQ ID NO:53);
His-Glu-Asn-Trp-Ser	(SEQ ID NO:54);
G[allyl-] N W G[allyl-]	(SEQ ID NO:55);
NH <sub>2</sub> Gr[allyl-] N W G[allyl-]	(SEQ ID NO:56);
Ac wn CO <sub>2</sub> H	(SEQ ID NO:57);
Ac NW CO <sub>2</sub> H	(SEQ ID NO:58);
Ac n w CO <sub>2</sub> H	(SEQ IDNO:59);
Ac N W BetaA CO <sub>2</sub> H	(SEQ ID NO:60); or
H E N W P CONH <sub>2</sub>	(SEQ ID NO:61).

60 (currently amended). The peptide according to claim 59 comprising at least one amino acid which is a D-isomer, an acylated N-terminus, and an acetylated N-terminus or amidated C-terminus.

61-63 (canceled).

64 (previously presented). A peptide of Claim 59 wherein said peptide is labeled with a detectable marker.

65 (currently amended). The peptide according to Claim 59 having a specific binding activity to CD23 of  $K_d = \underline{is}$  less than  $10^{-6}$  M.

66 (currently amended). The peptide according to Claim 40 65 wherein said peptide has a specific binding activity to CD23 of  $K_d$  comprised between at least about  $10^{-6}$  and  $10^{-11}$  M.